ACHE and Alzheimer disease: Currently, fosgonimeton is being evaluated in the late‐stage LIFT‐AD trial, a randomized, double‐blind, placebo‐controlled study designed to assess its safety and efficacy in mild to moderate AD patients not concurrently using acetylcholinesterase inhibitors.